Hypertrophic cardiomyopathy: a heart in need of an energy bar?

Abstract

Hypertrophic cardiomyopathy (HCM) has been recently recognized as the most common inherited cardiovascular disorder, affecting 1 in 500 adults worldwide. HCM is characterized by myocyte hypertrophy resulting in thickening of the ventricular wall, myocyte disarray, interstitial and/or replacement fibrosis, decreased ventricular cavity volume and diastolic dysfunction. HCM is also the most common cause of sudden death in the young. A large proportion of patients diagnosed with HCM have mutations in sarcomeric proteins. However, it is unclear how these mutations lead to the cardiac phenotype, which is variable even in patients carrying the same causal mutation. Abnormalities in calcium cycling, oxidative stress, mitochondrial dysfunction and energetic deficiency have been described constituting the basis of therapies in experimental models of HCM and HCM patients. This review focuses on evidence supporting the role of cellular metabolism and mitochondria in HCM.

A Good Heart Is Hard to Find

“…Finally,15O 2 is considered the gold standard for noninvasive estimation of MVȮ 2 because oxygen is the final electron acceptor in all pathways of aerobic metabolism. This approach yields absolute values of MVȮ 2 and is impervious to the confounding influence of pathological disease states. However, availability, logistics, and data analysis are challenging, making it unreliable and difficult to apply widely.…”

Utility of Exome Sequencing in A Familial Trio as A Diagnostic Tool in Cardiomyopathies

“…It is the most common inherited heart condition with an estimated prevalence of 1 in 500 in the general population [7]. The cardiac phenotype is variable even in patients carrying the same causal mutation [8]. SCD may be the first manifestation of the disease [9].…”

Haploinsufficiency MYBPC3 mutations: Another stress induced cardiomyopathy? Let's take a look!

“…At the cellular level, sarcomeric gene mutations are associated with enhanced calcium sensitivity, impairments in maximal force development, and ATPase activity [11]. These defects may converge to cause altered mitochondrial bioenergetics [12,13]. The clinical presentation can range from carriers who are never symptomatic to patients with moderate to severe symptoms.…”